Deucravacitinib Medicine 04 June 2026 Extended indication Extension of indication to include treatment of adult patients with moderate-to-severe SLE (exact indication text to be confirmed). Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Deucravacitinib Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Rheumatism Extended indication Extension of indication to include treatment of adult patients with moderate-to-severe SLE (exact indication text to be confirmed). Current proprietary name Already available biosimilars / generics Proprietary name Sotyktu Manufacturer BMS Portfolio holder BMS Mechanism of action JAK tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Orale selectieve tyrosinekinase 2 (TYK2) remmer. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Indication extension ATMP No Submission date January 2027 Expected Registration August 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Corticosteroïden, methotrexaat, azathioprine, mycofenolaat mofetil, cyclofosfamide, belimumab en anifrolumab. Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Er zijn nog geen resultaten bekend. Duration of treatment Frequency of administration Dosage per administration References NCT05617677 (POETYK SLE-1); NCT05620407 (POETYK SLE-2) Additional remarks Expected patient volume per year Patient volume 400 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Declaratiedata Additional remarks Er zijn minder dan 400 gebruikers van belimumab voor SLE. Er zijn echter nog altijd onvoldoende alternatieven voor de behandeling van SLE. Als het heel effectief blijkt zal het patiëntvolume mogelijk hoger uit kunnen komen. Expected cost per patient per year Cost References medicijnkosten.nl Additional remarks De prijs in Nederland is €731,71 (exclusief BTW) per verpakking met 28 tabletten. De totale kosten per jaar zijn afhankelijk van de dosering en behandelduur. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks